SCHEMBL4240795

SCHEMBL4240795

COC(=O)c1ccc(/C=C/C(=O)O)cc1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.69
ALDH1A1 P00352 6/20 0.69
HPGD P15428 5/20 0.69
HSD17B10 Q99714 4/20 0.69
SMN1; SMN2 Q16637 3/20 0.69
ALOX15 P16050 2/20 0.69
MAPK1 P28482 2/20 0.69
PKM P14618 3/20 0.66
SNCA P37840 3/20 0.66
CA12 O43570 2/20 0.66
CA1 P00915 2/20 0.66
CA2 P00918 2/20 0.66
CA3 P07451 2/20 0.66
CA4 P22748 2/20 0.66
CA6 P23280 2/20 0.66
CA5A P35218 2/20 0.66
CA7 P43166 2/20 0.66
CA9 Q16790 2/20 0.66
CA14 Q9ULX7 2/20 0.66
CA5B Q9Y2D0 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240801 1.00 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL17225903 0.89 NFKB1 (0.65) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL24593662 0.89 KDM4E (0.71) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL29738620 0.89 KDM4E (0.71) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL3910758 0.88 KDM4E (0.73) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL3910762 0.88 KDM4E (0.73) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL6959438 0.85 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL6959440 0.85 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
O,O'-Dimethylcaffeic Acid SCHEMBL81318 0.82 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
O,O'-Dimethylcaffeic Acid SCHEMBL81317 0.82 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9974779-B2 Piperidine derivatives as human papilloma virus inhibitors VAXART, INC. (US) 2018-05-22 US disclosed
US-20180021318-A9 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS VAXART, INC. 2018-01-25 US disclosed
US-20170079968-A1 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS AVIRAGEN THERAPEUTICS INC (US) 2017-03-23 US disclosed
US-9452991-B2 Piperidine derivatives as human papilloma virus inhibitors AVIRAGEN THERAPEUTICS, INC. (US) 2016-09-27 US disclosed
US-20120220633-A1 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS ANACONDA PHARMA 2012-08-30 US disclosed
US-8207373-B2 Benzoic acid derivatives as human papilloma virus inhibitors ANACONDA PHARMA (FR) 2012-06-26 US disclosed
US-20090209586-A1 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS ANACONDA PHARMA 2009-08-20 US disclosed
EP-0858452-B1 THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS OTSUKA PHARMA CO LTD (JP) 2002-03-13 EP disclosed
US-6140330-A USEFUL AS PROTEIN KINASE INHIBITOR; FOR TREATMENT OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, MULTIPLE SCLEROSIS, PSORIASIS, ETC., VARIOUS ALLERGIC DISEASES SUCH AS CROHN'S DISEASE, ASTHMA OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 2000-10-31 US disclosed
EP-0858452-A1 THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-08-19 EP disclosed
WO-1998004536-A1 THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1998-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170079968-A1 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS POLI, VHL, EBNA1BP2 KDM4E 1552/4885ALDH1A1 452/4885HPGD 490/4885
US-20180021318-A9 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS POLI, VHL, EBNA1BP2 KDM4E 1552/4885ALDH1A1 452/4885HPGD 490/4885
US-20090209586-A1 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS IDH3A, IDH1, CBR3 KDM4E 3037/4885ALDH1A1 123/4885HPGD 198/4885
US-20120220633-A1 PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS IDH3A, CBR3, CBR1 KDM4E 2892/4885ALDH1A1 138/4885HPGD 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.